Pneumonia News and Research

Latest Pneumonia News and Research

Pay-for-performance program may cause inequalities among healthcare providers

Pay-for-performance is an increasingly popular approach to improving health care quality. But the planned nationwide implementation of institutional bonuses mandated under federal health care reform threatens to act as a "reverse Robin Hood," potentially causing hospitals in less-advantaged regions to lose funds to health care facilities in more affluent areas of the country, according to a study published in the academic journal PLoS Medicine.

2 Jul 2010

Advanced Life Sciences prices securities offering

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has established the pricing terms of its proposed offering of units.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it's often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

29 Jun 2010

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.

29 Jun 2010

Health Canada recommends new pneumococcal vaccine for young children

In December, 2009, Health Canada approved a new vaccine for children aged six weeks through five years to prevent infections caused by the bacteria called pneumococcus or Streptococcus.

29 Jun 2010

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

The Associated Press: "Americans increasingly are treated to death, spending more time in hospitals in their final days, trying last-ditch treatments that often buy only weeks of time, and racking up bills that have made medical care a leading cause of bankruptcies. More than 80 percent of people who die in the United States have a long, progressive illness such as cancer, heart failure or Alzheimer's disease."

29 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

The quality of emergency medical care at the nation's hospitals varies widely - both individually and by state - according to a new HealthGrades study released today that, for the first time, examines mortality rates for patients entering hospitals through emergency departments.

23 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

Asthmatics to suffer more this winter warn experts

Asthma sufferers in Australia have been warned about a bad cold and flu season ahead. 58 percent of the susceptible population is already experiencing asthma attacks since the start of the season according to The National Asthma Council Australia (NACA) on Monday. They went on to say that nearly half of this population is still not vaccinated against seasonal flu.

21 Jun 2010

Model Formulary for Children provides information on how to use over 240 essential medicines

The first ever WHO Model Formulary for Children released by the WHO provides information on how to use over 240 essential medicines for treating illness and disease in children from 0 to 12 years of age. This means that for the first time medical practitioners worldwide have access to standardized information on the recommended use, dosage, adverse effects, and contraindications of these medicines for use in children.

18 Jun 2010

Yearlong collaborative partnership launched to reduce hospital readmissions due to heart failure

More than 5 million individuals in the United States suffer from chronic heart failure, making it one of the most common reasons for hospitalizations and readmissions. To address this costly issue, the New Jersey Hospital Association's Institute for Quality and Patient Safety this week launched a yearlong collaborative partnership to reduce hospital readmissions due to heart failure and improve the quality of healthcare in New Jersey.

18 Jun 2010

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company's supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence.

18 Jun 2010

Daily use of probiotics reduces VAP in critically ill patients: New research

Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.

17 Jun 2010

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

GAVI Alliance's plan to introduce new vaccine projects in the developing world "is under threat amid the international economic downturn," the Financial Times reports. "Subsidies to extend the use of vaccines against rubella, HPV to tackle cervical cancer, cholera and Japanese encephalitis in the developing world are among those likely to be cancelled or delayed," according to GAVI's CEO Julian Lob-Levyt, the newspaper writes.

17 Jun 2010

Pneumonia News and Research

Latest Pneumonia News and Research

Pay-for-performance program may cause inequalities among healthcare providers

Advanced Life Sciences prices securities offering

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

AlphaRx regains all rights to Indaflex from Cypress Bioscience

Health Canada recommends new pneumococcal vaccine for young children

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Asthmatics to suffer more this winter warn experts

Model Formulary for Children provides information on how to use over 240 essential medicines

Yearlong collaborative partnership launched to reduce hospital readmissions due to heart failure

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Daily use of probiotics reduces VAP in critically ill patients: New research

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Pneumonia News and Research

Latest Pneumonia News and Research

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in